uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

This study is testing uCD7 CAR-T cell therapy — a treatment where a patient's immune cells are engineered to find and destroy cancer cells carrying the CD7 protein — for people with relapsed or refractory CD7-positive blood cancers, including T-cell leukemia, T-cell lymphoma, and certain types of acute myeloid leukemia. **You may be eligible if:** - You are between 18 and 70 years old - You have been diagnosed with T-cell acute lymphoblastic leukemia/lymphoma or acute myeloid leukemia - Your cancer cells test positive for the CD7 protein - At least 5% of your bone marrow cells are cancer blasts - Your cancer has relapsed or has not responded to prior treatment **You may NOT be eligible if:** - Your cancer cells do not express CD7 - You have not had prior treatment (this is for relapsed/refractory cases) - You have serious organ problems that make CAR-T therapy unsafe Talk to your doctor to see if this trial is right for you.